BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
October 19 2020 - 3:15PM
Business Wire
BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and
Nasdaq: BLU), announced today the filing of a preliminary
prospectus supplement (the “Supplement”) to its short form base
shelf prospectus dated January 17, 2020 (the “Base Prospectus”) in
connection with a proposed public offering of its common shares
(the “Offering”). The Supplement was filed with each of the
securities regulatory authorities in the provinces of Canada. The
Supplement and accompanying Base Prospectus were also filed with
the U.S. Securities and Exchange Commission (the “SEC”) as part of
a registration statement on Form F-10, as it may be amended from
time to time, in accordance with the Multijurisdictional Disclosure
System established between Canada and the United States. The
Company intends to use the net proceeds of the Offering primarily
to fund research and development activities, general and
administrative expenses, working capital needs and other general
corporate purposes, as set out in the Supplement.
The Company also expects to grant to the underwriters a 30-day
option to purchase up to an additional 15% of the number of common
shares offered in the Offering. The Offering is expected to be
priced in the context of the market, with the final terms of the
Offering to be determined at the time of pricing. There can be no
assurance as to whether or when the Offering may be completed, or
as to the actual size or terms of the Offering. The closing of the
Offering will be subject to customary closing conditions including
approval from the TSX. For the purposes of the TSX approval, the
Company intends to rely on the exemption set forth in Section 602.1
of the TSX Company Manual, which provides that the TSX will not
apply its standards to certain transactions involving eligible
interlisted issuers on a recognized exchange, such as Nasdaq.
Jefferies and Evercore ISI are acting as joint book-running
managers. LifeSci Capital is acting as co-manager for the
Offering.
The Supplement and the accompanying Base Prospectus contain
important detailed information about the Offering. The Supplement
and the accompanying Base Prospectus can be found on SEDAR at
www.sedar.com and on EDGAR at www.sec.gov. Copies of the Supplement
and accompanying Base Prospectus may also be obtained from the
Company, by telephone at 450-680-4500 or by email at
info@bellushealth.com or you may request them from: Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-821-7388
or by email at prospectus_department@jefferies.com; or Evercore
Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd
Street, 35th Floor, New York, NY 10055, by telephone at
888-474-0200 or by email at ecm.prospectus@evercore.com.
Prospective investors should read the Supplement and accompanying
Base Prospectus and the other documents the Company has filed
before making an investment decision.
No regulatory authority has either approved or disapproved the
contents of this news release. This news release shall not
constitute an offer to sell or the solicitation of an offer to buy,
nor shall there be any sale of these securities in any province,
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to the registration or qualification under
the securities laws of any such province, state or
jurisdiction.
About BELLUS Health
BELLUS Health is a clinical-stage biopharmaceutical company
developing novel therapeutics for the treatment of chronic cough
and other hypersensitization-related disorders. The Company’s
product candidate, BLU-5937, is being developed for the treatment
of chronic cough and chronic pruritus.
Cautionary Note Regarding Forward-‐Looking
Statements
Certain statements contained in this news release may constitute
“forward-looking statements” within the meaning of applicable
securities laws. Such statements, based as they are on the current
expectations of management, inherently involve numerous important
risks, uncertainties and assumptions, known and unknown. In this
news release, such forward-looking statements include, but are not
limited to, statements regarding the Offering, the granting of the
option to purchase additional shares and the anticipated use of
proceeds from the Offering. Completion of the Offering is subject
to numerous factors, many of which are beyond BELLUS Heath’s
control, including but not limited to, market conditions, the
failure of the parties to satisfy certain closing conditions and
other important factors disclosed previously and from time to time
in BELLUS Health’s filings with the securities regulatory
authorities in each of the provinces and territories of Canada and
the SEC. Actual future events may differ from the anticipated
events expressed in such forward-looking statements. BELLUS Health
believes that expectations represented by forward-looking
statements are reasonable, yet there can be no assurance that such
expectations will prove to be correct. The reader should not place
undue reliance, if any, on any forward-looking statements included
in this news release. These forward-looking statements speak only
as of the date made, and BELLUS Health is under no obligation and
disavows any intention to update publicly or revise such statements
as a result of any new information, future event, circumstances or
otherwise, unless required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201019005834/en/
Finance: Francois Desjardins Vice President, Finance
fdesjardins@bellushealth.com
Investors: Danny Matthews Director, Investor Relations
and Communications danny@bellushealth.com
BELLUS Health (TSX:BLU)
Historical Stock Chart
From Mar 2024 to Apr 2024
BELLUS Health (TSX:BLU)
Historical Stock Chart
From Apr 2023 to Apr 2024